Starting January 1, 2025, benefits for GLP-1 medications will be eliminated from base plans for patients with a BMI under 40 when prescribed solely for reducing body mass
When I prescribe Mounjaro which already produces results we have never seen before I am acutely aware that retatrutide could represent another step change
Back Drucker, DJ, Mojsov, S, Habener, JF (25 July 1986) 'Cell-specific post-translational processing of preproglucagon expressed from a metallothionein-glucagon fusion gene', Journal Biological Chemistry , 261/21, 9637-43
T., Leprevost, F
For someone on a GLP-1 medication where transit time is already extended, this can make the difference between a comfortable daily bowel movement and going 3-4 days without one
National Library of Medicine Tesamorelin phase III trial registrations (NCT00435136, NCT00123253, NCT00608023)